Cannabis Edibles Legalization Fails to Save Pot Stocks, Including Hexo (TSX:HEXO)

The legalization of edibles failed to lift cannabis stocks or the appeal of investing in Hexo Corp. (TSX:HEXO)(NYSE:HEXO).

| More on:
Marijuana plant and cannabis oil bottles isolated

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s premium investing services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn more

The legalization of cannabis edibles and derivative products last month has failed to give cannabis stocks a desperately needed lift. Leading cultivators Aurora Cannabis, Canopy Growth, and Aphria have been heavily marked down by the market since the start of 2019, losing 54%, 36%, and 23%, respectively. Even Hexo (TSX:HEXO)(NYSE:HEXO), which is positioning itself to become a market leader in the edibles space through an alliance with Molson Coors and is the first major grower to join Food & Consumer Products of Canada, has been hammered, losing 45% for the year to date.

This has sparked considerable speculation that it has created an opportunity to acquire quality marijuana stocks, which are poised to soar once Health Canada’s waiting period ends and approved cannabis edibles are available for sale. This is expected to occur on December 17, 2019, and, according to industry participants as well as analysts, will give demand for legally cultivated cannabis a significant lift, which will be a boon for the major cultivators.

Declining outlook

If the experience of Colorado and California is anything to go by, the introduction of legally available edible cannabis products will be met by a stampede of demand, causing the consumption of cannabis flower to soar. Canada’s edibles and extracts market is estimated to be worth up to $2.7 billion.

The considerable pent-up demand for those products, beverages, vapes, and other extract-based products will give demand for legally cultivated marijuana a notable boost. That should translate into higher sales and hence earnings for the major cultivators. Edibles are also far more appealing to many consumers because of the stigma associated with smoking dried cannabis flower.

Nonetheless, the are signs that Cannabis 2.0 may not have the anticipated effect. Health Canada has advised that only a limited selection will be available in December, while provincial regulatory bodies have advised that there will be a slow introduction of products.

There are also fears that the introduction of edibles will lead to a spike in hospital admissions, as has occurred in Colorado. That will trigger greater regulatory scrutiny at provincial and federal levels.

Rising uncertainty over the supply of cannabis edibles combined with growing flower supply and sharply lower-than-anticipated demand for cannabis over the year since it was legalized bode poorly for cultivators. This magnifies fears that pot stocks are trading with lofty valuations and won’t be able to expand sales as predicted, or profit in an industry where profitability appears elusive for most participants.

Hexo reported a $57 million loss for its fiscal fourth quarter 2019, which was just over five times greater than a year earlier. It is also burning cash at a tremendous rate with operating expenses growing more than fourfold compared to the same period a year earlier.

There was also a sharp increase in the number of shares issued on a fully diluted basis, which grew by a whopping 29% year over year to 303 million shares. That is bad news for existing shareholders, because it indicates that they are being diluted by Hexo, as it uses equity to fund the expansion of its business in an environment where its market value is falling.

On a positive note, Hexo finished the latest reported quarter with almost $114 million in cash and negligible long-term debt of $30 million.

Foolish takeaway

The dilution of existing shareholders, a nosebleed valuation that sees Hexo trading at over 15 times sales, and never having reported a profit in an industry with an uncertain outlook make it an unattractive stock. Those factors indicate that Hexo could have further to fall, even with the legalization of marijuana edibles, beverages, and extract-based products, making it an unattractive investment at this time.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Matt Smith has no position in any of the stocks mentioned. The Motley Fool owns shares of Molson Coors Brewing. The Motley Fool recommends HEXO. and HEXO.

More on Cannabis Stocks

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Canopy Growth Stock: The Only Cannabis Stock to Consider Long Term

The cannabis stock industry remains an incredibly high risk one, but Canopy Growth (TSX:WEED)(NYSE:CGC) stock provides the best opportunity for…

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Should You Stay Away From HEXO Stock?

HEXO (TSX:HEXO)(NASDAQ:HEXO) stock is on a downward spiral, and there is little hope it is going to recover soon.

Read more »

edit Cannabis leaves of a plant on a dark background
Cannabis Stocks

Why Did Aurora Cannabis (TSX:ACB) Stock Plunge 75% in 2022?

A prominent cannabis stock has plunged by 75% in 2022, as the company’s losses continue to mount in the face…

Read more »

Pot stocks are a riskier investment
Cannabis Stocks

Fire & Flower: A Small Pot Stock Poised for Strong Growth

Fire & Flower is a cannabis retailer well-positioned for growth thanks to its digital and delivery initiatives.

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Is Sinking This Week

Starting another round of capital raising has hurt investor sentiments, and the Canadian cannabis giant’s performance on the stock market…

Read more »

edit Jars of marijuana
Cannabis Stocks

Why Canopy Growth (TSX:WEED) Stock Plunged 19% Last Week

Canopy Growth Corp. (TSX:WEED)(NASDAQ:CGC) stock has plunged after the release of its final fiscal 2022 results.

Read more »

Cannabis stocks have fallen.
Cannabis Stocks

Why Aurora Cannabis (TSX:ACB) Stock Tanked 45% Last Week

There's no respite for Aurora Cannabis investors!

Read more »

Money growing in soil , Business success concept.
Cannabis Stocks

TFSA Investors: This Undervalued Gem Could Turn $6,000 Into $25,000

Here's why TFSA investors can hold undervalued growth stocks such as Verano in their portfolios right now.

Read more »